Communiqués Alnylam Pharmaceuticals, Inc.

Actions

ALNY

US02043Q1076

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
152,8 ^USD	+2,33 %		+2,93 %	-20,18 %

03/06	Un initié d'Alnylam Pharmaceuticals a vendu des actions pour une valeur de 3 224 546 $, selon un récent dépôt auprès de la SEC	MT
07/05	ALNYLAM PHARMACEUTICALS, INC. : HC Wainwright à l'achat	ZM

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Alnylam Issues 2023 Corporate Responsibility Report	07/05	BU
Alnylam Pharmaceuticals : 2023 REPORT	07/05	PU
Alnylam Pharmaceuticals : Q1 2024 GAAP/Non-GAAP Reconciliation ›	02/05	PU
Alnylam: Q1 Earnings Snapshot	02/05	AQ
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity	02/05	BU
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia	30/04	PR
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results	18/04	BU
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension	08/04	AQ
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension	07/04	BU
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session	20/03	BU
Alnylam Launches Hereditary ATTR Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease	14/03	AQ
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease	13/03	BU
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY	12/03	PR
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure	06/03	AQ
Alnylam annonce des résultats positifs de l’étude KARDIA-2 démontrant des réductions cliniquement significatives de la pression artérielle lorsque le zilebesiran est ajouté à des antihypertenseurs standards	05/03	BU
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives	05/03	BU
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY	03/03	PR
Alnylam to Webcast Presentations at Upcoming March Investor Conferences	27/02	BU
Alnylam: Q4 Earnings Snapshot	15/02	AQ
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity	15/02	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Alnylam Pharmaceuticals, Inc.

Actions

ALNY

US02043Q1076

Communiqués

Filtres